Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A personalized mRNA cancer vaccine is changing the melanoma playbook. The phase 3 INTerpath-001 trial found that adding intismeran autogene to standard pembrolizumab therapy cut the risk of recurrence or death by 42% and distant metastasis or death by 38% in patients with completely resected high-risk melanoma. Results were presented early at ESMO 2026 after a data leak.
A personalized mRNA cancer vaccine is reshaping how oncologists think about post-surgery melanoma treatment. The phase 3 INTerpath-001 trial — presented at ESMO Congress 2026 — found that combining intismeran autogene (V940/mRNA-4157, developed by Merck and Moderna) with standard adjuvant pembrolizumab cut the risk of recurrence or death by 42% and the risk of distant metastasis or death by 38% compared to pembrolizumab alone, in patients with completely resected stage IIB–IV melanoma.
The vaccine works by targeting patient-specific, tumor-derived antigens — essentially tailoring treatment to the unique mutational fingerprint of each patient's tumor. With a median follow-up of 24.6 months, neither group had reached median recurrence-free survival (RFS), but 2-year RFS rates clearly favored the combination. Overall survival data remain immature, though a favorable trend was observed. The safety profile was manageable, with grade 3+ adverse events occurring at similar rates in both groups.
By the Numbers:
Why it matters: This is the first phase 3 trial to validate a personalized mRNA cancer vaccine in a large randomized setting, building on earlier phase 2 signals. If approved, it could mark a foundational shift in adjuvant cancer care — and the technology is already being explored across lung, pancreatic, and gastric cancers.
